<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We carried out bone marrow transplantation (BMT) in 50 patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) who were 55.3 to 66.2 years of age (median, 58.8 years) </plain></SENT>
<SENT sid="1" pm="."><plain>According to the criteria of the French-American-British (FAB) classification, 13 patients had <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (RA), 19 had RA with excess blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>), 16 had <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in transformation or <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), and 2 had <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>According to the recently established International Prognostic Scoring System (IPSS), available for 45 patients, 2 patients were considered low risk; 14, intermediate 1 risk; 19, intermediate 2 risk; and 10, high risk </plain></SENT>
<SENT sid="3" pm="."><plain>Conditioning regimens were <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (CY) (120 mg/kg of body weight) plus 12-Gy fractionated total-body irradiation (FTBI) (n = 15), CY plus FTBI with lung and liver shielding (n = 4), <z:chebi fb="0" ids="28901">busulfan</z:chebi> (7 mg/kg) plus FTBI (n = 4), or <z:chebi fb="0" ids="28901">busulfan</z:chebi> (16 mg/kg) plus CY (n = 27) </plain></SENT>
<SENT sid="4" pm="."><plain>The <z:chebi fb="0" ids="28901">busulfan</z:chebi>-plus-CY group included 16 patients in whom <z:chebi fb="0" ids="28901">busulfan</z:chebi> was targeted to plasma levels of 600 to 900 ng/mL </plain></SENT>
<SENT sid="5" pm="."><plain>In these 16 patients, steady-state levels of <z:chebi fb="0" ids="28901">busulfan</z:chebi> actually achieved were 714 to 961 ng/mL (mean +/- SD, 845 +/- 64 ng/mL; median, 838 ng/mL) </plain></SENT>
<SENT sid="6" pm="."><plain>The donors were HLA-identical siblings for 34 patients, HLA-nonidentical family members for 4, identical twins for 4, and unrelated volunteers for 6 </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> 46 patients surviving &gt; 21 days had engraftment, and 22 patients (44%) are surviving 9 to 80 months after BMT </plain></SENT>
<SENT sid="8" pm="."><plain>Specifically, among 13 patients with RA, 1 had relapse (cumulative incidence [CI] at 3 years, 8%) and 8 are surviving, for a Kaplan-Meier (KM) estimate of survival at 3 years of 59% (disease-free survival [DSF], 53%) </plain></SENT>
<SENT sid="9" pm="."><plain>Among 19 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, 3 had relapse (CI at 3 years, 16%), and 8 are surviving disease free (KM estimate at 3 years, 46%) </plain></SENT>
<SENT sid="10" pm="."><plain>Among 18 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>, 6 had relapse (CI at 3 years, 28%), and the KM estimate of DSF at 3 years is 33% </plain></SENT>
<SENT sid="11" pm="."><plain>Relapse-free survival had an inverse correlation with cytogenetic risk classification and with the risk score according to the IPSS </plain></SENT>
<SENT sid="12" pm="."><plain>Survival in <z:hpo ids='HP_0000001'>all</z:hpo> FAB categories was highest among patients enrolled in a protocol in which <z:chebi fb="0" ids="28901">busulfan</z:chebi> plasma levels were targeted to 600 to 900 ng/mL </plain></SENT>
<SENT sid="13" pm="."><plain>These data indicate that BMT can be carried out successfully in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> who are older than 55 years of age </plain></SENT>
<SENT sid="14" pm="."><plain>(Blood </plain></SENT>
<SENT sid="15" pm="."><plain>2000;95:1188-1194) </plain></SENT>
</text></document>